Halozyme Therapeutics, Inc. leadership

Dr. Torley has served as President and Chief Executive Officer of Halozyme since 2014 and led the company through a strategic transition in 2019. She previously served as Chief Commercial Officer at Onyx Pharmaceuticals from 2011 to 2013, leading the U.S. launch of Kyprolis, and held senior commercial positions at Amgen from 2002 to 2011, including Vice President and General Manager of U.S. Bone Health and U.S. Nephrology. Earlier she held sales and marketing leadership roles at Bristol-Myers Squibb and clinical development roles at Sandoz/Novartis, culminating as Vice President of Medical Affairs. She previously served on the public company board of Quest Diagnostics Incorporated and holds an M.B.Ch.B. from the University of Glasgow and her M.R.C.P. from the Royal College of Physicians, Glasgow.

Mr. Henderson has served as the independent Chair of the Board of Directors since May 2022 and is a member of the Audit Committee. He is President of JWH Consulting LLC, an investment and business advisory firm, since January 2018, and previously served as a Healthcare Advisory Director to Berkshire Partners LLC from 2015 to 2019. He was Chief Financial Officer of Cardinal Health, Inc. from May 2005 until November 2014 and held senior management positions at Eli Lilly and Company from 1998 to 2005, including President and General Manager of Eli Lilly Canada. He currently serves on the public company boards of Becton Dickinson and Company and Qualcomm, Inc., and previously served on the board of Fibrogen, Inc.

Ms. Connaughton brings more than 30 years of global strategic, commercial and biopharmaceutical industry experience to the Board and chairs the Compensation Committee. From 2004 to October 2017 she held senior management positions at Bristol-Myers Squibb, most recently as president of the region covering China, Latin America, Central and Eastern Europe and the Middle East, and earlier as president of European Markets, Canada and Australia; Intercontinental; and Japan, Pacific Rim, Australia and Canada. She currently serves on the public company board of Editas Medicine, Inc. and previously served on the boards of Syneos Health Inc. and Zealand Pharma A/S. She holds a Bachelor of Arts from Johns Hopkins University and an MBA from The Wharton School, University of Pennsylvania.

Mr. Posard brings over 30 years of general management and commercialization experience in the biotechnology and diagnostics industry to the Board, where he chairs the Nominating and Corporate Governance Committee and serves on the Audit Committee. He is Founding Principal of Explore DNA, a life sciences executive consulting firm, a position held since March 2016, and previously served as President and Chief Commercial Officer of GenePeeks, Inc. and Chief Commercial Officer of Trovagene, Inc. From February 2006 to February 2015 he held various commercial and general management positions at Illumina, Inc., including overseeing global sales and serving as general manager of Clinical and Consumer Genomics. He currently serves as Chairman of the board of Nautilus Biotechnology, Inc. and previously served on the boards of Talis Biomedical and DermTech, Inc.

Ms. Duncan brings over 16 years of pharmaceutical and biotechnology industry experience to the Board, where she chairs the Audit Committee and serves on the Compensation Committee and is designated an audit committee financial expert. She served as Chief Financial Officer and Treasurer of Intercept Pharmaceuticals, Inc. from May 2009 to June 2016 and held senior leadership roles at DOV Pharmaceutical, Inc. from 2001 to 2009, ultimately serving as Chief Executive Officer prior to its 2010 sale to Euthymics Bioscience. Earlier she worked at Lehman Brothers Inc., SBC Warburg Dillon Read Inc., PepsiCo, Inc., and Deloitte & Touche LLP. She currently serves on the public company boards of Atea Pharmaceuticals, Inc. and Ovid Therapeutics, Inc., and holds a BBA from Louisiana State University and an MBA from The Wharton School.

Dr. Krishnan brings more than 20 years of health care practitioner and biotechnology and health service industry experience to the Board and serves on the Nominating and Corporate Governance Committee and the Compensation Committee. Since 2009 he has held various roles at DaVita, Inc., including co-lead of DaVita Venture Group and Group Vice President of Research and Development, and previously served as DaVita's first international Chief Medical Officer from 2015 to May 2019. From 2004 to 2009 he held various roles at Amgen Inc., including Global Development Leader for Epogen, and from 2000 to 2004 was a practicing nephrologist at Virginia Nephrology Group. He previously served on the public company board of Chinook Therapeutics, Inc., and holds an M.D. from Jefferson Medical College, a B.S. from Pennsylvania State University, an M.P.H. from Johns Hopkins University, and an MBA from the Johns Hopkins Carey School of Business.

Mr. Lang brings more than 30 years of experience in healthcare data, analytics, and technology-enabled business services to the Board. From May 2017 to August 2025 he served as founder and Chief Executive Officer of EVERSANA, a provider of global commercialization services for the life sciences industry, and since December 2016 has served as an executive advisor to Water Street Healthcare Partners. He previously held leadership roles at Decision Resources Group, including Chief Executive Officer from 2014 to 2016, served as President of IHS Cambridge Energy Research Associates, and held various roles at Strategic Decisions Group including President and Chief Operating Officer. He currently serves on the public company boards of BioVie, Inc. and OptimizeRX Corporation, and holds a BS from the University of New Hampshire and an MBA from the Tuck School of Business.

Ms. Miyashita is an independent member of Halozyme's Board of Directors and serves on the Compensation Committee. The Board determined that she is an independent director within the meaning of the applicable rules of the NASDAQ Stock Market. She is not standing for re-election, and her term expires as of the date of the 2026 Annual Meeting.

Ms. LaBrosse serves as Senior Vice President and Chief Financial Officer of Halozyme and was appointed to the Chief Financial Officer role on February 2, 2022. She is one of Halozyme's Named Executive Officers for 2025.

Mr. Snyder serves as Senior Vice President and Chief Legal Officer of Halozyme and also serves as the Company's General Counsel and Corporate Secretary. He commenced employment with Halozyme on January 3, 2022 and is one of the Company's Named Executive Officers for 2025.

Ms. Caudill serves as Senior Vice President and Chief Operating Officer of Halozyme, having been promoted to that role on October 1, 2025. She previously served as Senior Vice President, Chief Operations Officer beginning in October 2023, and is one of the Company's Named Executive Officers for 2025.

Mr. LaBarre served as Senior Vice President and Chief Technical Officer of Halozyme until his retirement from the Company on March 17, 2025. He is identified as one of the Company's Named Executive Officers for 2025.